Progress in research of HPV vaccine and influencing factors in process of promotion and vaccination

doi:10.3877/cma.j.issn.1674-0785.2021.03.013

Abstract

Abstract:

HPV infection is the main cause of cervical cancer and other HPV-related diseases. There has been a remarkable decline in the morbidity and mortality of cervical cancer and its related diseases after the popularization and application of HPV vaccines in the past ten years. HPV vaccine has only been recently licensed in China, and there are still many influencing factors in the process of promotion and vaccination, e.g., adverse events, lower awareness rate, high cost, supply shortage, worry about safety and effectiveness, and lack of HPV-related knowledge. This paper reviews the progress in the research of HPV and HPV vaccine and the influencing factors in the popularization and application of HPV vaccine in order to provide information to help increase the coverage rate of HPV vaccine and develop a new locally produced HPV vaccine that is cheap, safe, and effective.

Key words: Human papillomavirus, Vaccine, Adverse event, Knowledge

Xumei Yang, Rongrong Jin, Huiling Zhou, Xiaoqin Jiang, Hong Yu. Progress in research of HPV vaccine and influencing factors in process of promotion and vaccination[J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(03): 218-223.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2021.03.013

https://zhlcyszz.cma-cmc.com.cn/EN/Y2021/V15/I03/218

References 49

1	Ciccarese G, Herzum A, Rebora A, et al. Prevalence of genital, oral, and anal HPV infection among STI patients in Italy [J]. J Med Virol, 2017, 89(6): 1121-1124.
2	Thomas TL. Cancer prevention: HPV vaccination [J]. Semin Oncol Nurs, 2016, 32(3): 273-280.
3	Viens LJ, Henley SJ, Watson M, et al. Human papillomavirus-associated cancers-United States, 2008-2012 [J]. MMWR Morb Mortal Wkly Rep, 2016, 65(26): 661.
4	Stojanov IJ, Woo SB. Human papillomavirus and Epstein-Barr virus associated conditions of the oral mucosa [J]. Semin Diagn Pathol, 2015, 32(1): 3-11.
5	Markowitz LE, Liu G, Hariri S, et al. Prevalence of HPV after introduction of the vaccination program in the United States [J]. Pediatrics, 2016, 137(3): 1-9.
6	Garland SM, Kjaer SK, Muñoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: A systematic review of 10 years of real-world experience [J]. Clin Infect Dis, 2016, 63(4): 519-527.
7	Bednarczyk RA. Addressing HPV vaccine myths: practical information for healthcare providers [J]. Hum Vaccin Immunother, 2019, 15(7-8): 1628-1638.
8	Holloway GL. Effective HPV vaccination strategies: what does the evidence say? An integrated literature review [J]. J Pediatr Nurs, 2019, 44: 31-41.
9	Lowy DR, Schiller JT. Reducing HPV-associated cancer globally [J]. Cancer Prev Res (Phila), 2012, 5(1): 18-23.
10	Kreimer AR, Clifford GM, Boyle P, et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review [J]. Cancer Epidemiol Biomarkers Prev, 2005, 14(2): 467-475.
11	Van Dyne EA, Henley SJ, Saraiya M, et al. Trends in human papillomavirus-associated cancers-United States, 1999-2015 [J]. MMWR Morb Mortal Wkly Rep, 2018, 67(33): 918-924.
12	Gallagher KE, LaMontagne DS, Watson-Jones D. Status of HPV vaccine introduction and barriers to country uptake [J]. Vaccine, 2018, 6(32): 4761-4767.
13	Saraiya M, Unger ER, Thompson TD, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines [J]. J Natl Cancer Inst, 2015, 107(6): djv086.
14	Petrosky E, Bocchini JAJr, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices [J]. MMWR Morb Mortal Wkly Rep, 2015, 64(11): 300-304.
15	Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia [J]. N Engl J Med, 2011, 365(17): 1576-1585.
16	Harder T, Wichmann O, Klug SJ, et al. Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review [J]. BMC Med, 2018, 16(1): 110.
17	Centers for Disease Control and Prevention (CDC). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP) [J]. MMWR Morb Mortal Wkly Rep, 2010, 59(20): 630-632.
18	World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations [J]. Vaccine, 2017, 35(43): 5753-5755.
19	Siu JY, Lee A, Chan PKS. Schoolteachers' experiences of implementing school-based vaccination programs against human papillomavirus in a Chinese community: a qualitative study [J]. BMC Public Health, 2019, 19(1): 1514.
20	Villa A, Patton LL, Giuliano AR, et al. Summary of the evidence on the safety, efficacy, and effectiveness of human papillomavirus vaccines [J]. J Am Dent Assoc, 2020, 151(4): 245-254.e24.
21	陈飞, 吕嬿, 沈铿. 重视和正确认识HPV疫苗的安全性 [J]. 中华妇产科杂志, 2019, 54(4): 217-220.
22	Costa APF, Cobucci RNO, Da Silva JM, et al. Safety of human papillomavirus 9-valent vaccine: a meta-analysis of randomized trials [J]. J Immunol Res, 2017, 2017: 1-6.
23	Moreira EDJr, Block SL, Ferris D, et al. Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase Ⅲ clinical trials [J]. Pediatrics, 2016, 138(2): e20154387.
24	Dorell C, Stokley S, Yankey D, et al. National and State vaccination coverage among adolescents aged 13-17 years-United States, 2012 [J]. MMWR Suppl, 2012, 61(34): 671-677.
25	Deleré Y, Böhmer MM, Walter D, et al. HPV vaccination coverage among women aged 18-20 y in Germany three years after recommendation of HPV vaccination for adolescent girls: Results from a cross-sectional survey [J]. Hum Vaccin Immunother, 2013, 9(8): 1706-1711.
26	Li SL, Lau YL, Lam TH, et al. HPV vaccination in Hong Kong: uptake and reasons for non-vaccination amongst Chinese adolescent girls [J]. Vaccine, 2013, 31(49): 5785-5788.
27	Zhao FH, Tiggelaar SM, Hu SY, et al. A multi-center survey of HPV knowledge and attitudes toward HPV vaccination among women, government officials, and medical personnel in China [J]. Asian Pac J Cancer Prev, 2012, 13(5): 2369-2378.
28	Chen L, Song Y, Ruan G, et al. Knowledge and attitudes regarding HPV and vaccination among Chinese women aged 20 to 35 years in Fujian Province [J]. Cancer Control, 2018, 25(1): 107327481877535.
29	He J, He L. Knowledge of HPV and acceptability of HPV vaccine among women in western China: a cross-sectional survey [J]. BMC Womens Health, 2018, 18(1): 130.
30	Osazuwa-Peters N, Adjei Boakye E, Mohammed KA, et al. Not just a woman's business! Understanding men and women's knowledge of HPV, the HPV vaccine, and HPV-associated cancers [J]. Prev Med, 2017, 99: 299-304.
31	Li J, Zheng H. Coverage of HPV-related information on Chinese social media: a content analysis of articles in Zhihu [J]. Hum Vaccin Immunother, 2020, 16(10): 2548-2554.
32	Yin Y. HPV vaccination in China needs to be more cost-effective [J]. Lancet, 2017, 390(10104): 1735-1736.
33	Wang W, Ma Y, Wang X, et al. Acceptability of human papillomavirus vaccine among parents of junior middle school students in Jinan, China [J]. Vaccine, 2015, 33(22): 2570-2576.
34	王少明, 乔友林. HPV预防性疫苗在中国的应用前景 [J]. 癌症进展, 2010, 8(2): 134-138.
35	Wong LP, Han L, Li H, et al. Current issues facing the introduction of human papillomavirus vaccine in China and future prospects [J]. Hum Vaccin Immunother, 2019, 15(7-8): 1533-1540.
36	Zhao F, Qiao Y. Cervical cancer prevention in China: a key to cancer control [J]. Lancet, 2019, 393(10175): 969-970.
37	Garland SM, Stanley MA, Giuliano AR, et al. IPVS statement on "Temporary HPV vaccine shortage: Implications globally to achieve equity" [J]. Papillomavirus Res, 2020, 9: 100195.
38	Xie J. HPV vaccine market burst [N]. Global Times, 2018-03-19.
39	Wang XQ, Hancock T. Chinese medical tourism exacerbates shortage of HPV vaccine [N]. Financial Times, 2018-06-15.
40	张师前, 王凯, 张远丽. HPV疫苗在中国的应用现状 [J]. 中国实用妇科与产科杂志, 2019, 35(10): 22-27.
41	Arbyn M, Bryant A, Beutels P, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors (Protocol) [J]. Cochrane Database Syst Rev, 2011, 5(5): CD009069.
42	Shelal Z, Cho D, Urbauer DL, et al. Knowledge matters and empowers: HPV vaccine advocacy among HPV-related cancer survivors [J]. Support Care Cancer, 2020, 28(5): 2407-2413.
43	Zhang Y, Wang Y, Liu L, et al. Awareness and knowledge about human papillomavirus vaccination and its acceptance in China: a meta-analysis of 58 observational studies [J]. BMC Public Health, 2016, 16: 216
44	Qiu J, Hu H, Zhou S, et al. Vaccine scandal and crisis in public confidence in China [J]. Lancet, 2016, 387(10036): 2382.
45	The Lancet. Vaccine scandal and confidence crisis in China [J]. Lancet, 2018, 392(10145): 360.
46	Lenselink CH, Gerrits MM, Melchers WJ, et al. Parental acceptance of human papillomavirus vaccines [J]. Eur J Obstet Gynecol Reprod Biol, 2008, 137(1): 103-107.
47	Kasting ML, Shapiro GK, Rosberger Z, et al. Tempest in a teapot: A systematic review of HPV vaccination and risk compensation research [J]. Hum Vaccin Immunother, 2016, 12(6): 1435-1450.
48	Madhivanan P, Pierre-Victor D, Mukherjee S, et al. Human papillomavirus vaccination and sexual disinhibition in females: a systematic review [J]. Am J Prev Med, 2016, 51(3): 373-383.
49	Zhao FH, Tiggelaar SM, Hu SY, et al. A multi-center survey of HPV knowledge and attitudes toward HPV vaccination among women, government officials, and medical personnel in China [J]. Asian Pac J Cancer Prev, 2012, 13(5): 2369-2378.

[1]	Li Zhang, Xiao Yang, Wen Chen, Jian Wang, Bo Zhao, Zhou Jing, Yahong Wang, Sheng Cai, Yuxin Jiang, Jianchu Li. Design of graduation assessment of China's standardized training for ultrasound residents based on disease-knowledge ability system [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2022, 19(11): 1274-1280.
[2]	Yiqun Li, Na Wang, Hongnan Mo, Bo Lan, Jiani Wang, Tingyu Wen, Fei Ma. Vaccination against COVID-19 and influencing factors in patients with early breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(01): 30-35.
[3]	Meicen Zhou, Hua Wang, Dezhi Mu. Vaccination timeliness in preterm infants: a review of literature [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(03): 261-266.
[4]	Min Miao, Honglin Yang, Yang Liu, Lin Pang. Clinical characteristics of measles in unvaccinated and vaccinated children [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(02): 110-116.
[5]	Bitao Wang, Zheng Wang, Guobin Wang. Treatment status and progress of Lynch syndrome [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(03): 332-335.
[6]	Committee of Health Management for Organ Transplant Recipient, China Organ Transplantation Development Foundation. Expert guidance on prophylaxis strategies and health management of organ transplant recipients infected with COVID-19 in China (first edition) [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(01): 1-12.
[7]	Xia Li, Li Meng, Kang Gao, Minna Bai, Meifen Zhang. Construction and application effect of the core knowledge system of Urology specialized nurses training [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(06): 621-626.
[8]	Mi Li, huajuan Qiu, Yanqin Ji, Minghui Zhou. Effect of P16 and Ki67 expression and viral load detection on outcome of cervical lesions in woman of childbearing age with cervical intraepithelial neoplasia grade Ⅱ complicated with high-risk human papillomavirus infection [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(03): 272-278.
[9]	Guowang Yang, Zhen Bian, Yumeng Ji, Yixuan Li, Shiwen Chen, jianling Gao, Xin Jin. Investigation of 81 cases of adverse events during perianesthesia period in primary hospitals in Jiangsu province [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(02): 136-141.
[10]	Yongyang Yun, Xiaodan Zhang, Yuanjia Cheng, Mingshuai Sun, Ling Xin, Qian Liu, Yinhua Liu, Xuening Duan, Zhuo Zhang, Qianxin Liu, Yimin Cui, Qian Xiang, Ling Xu. Adverse events of TCHP neoadjuvant therapy in patients with human epidermal growth factor receptor 2 positive breast cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(11): 1075-1080.
[11]	Yu Qin, Miao Yang, Kai Chang, Shuning. Wang. Analysis of the current situation of human papillomavirus infection in females in Shanxi Province [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2023, 11(02): 105-108.
[12]	Ting Yang, Xiaojue Qiu, Qingya Chen, Baojing Zhang, Weiwei Wang. Establishment and evaluation of a prediction model for pancreatitis after transendoscopic retrograde cholangiopancreatography [J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2023, 10(03): 200-204.
[13]	Xiangli Sun, Zhenzhen Xu. Efficacy of percutaneous coronary rotational atherectomy for severe calcification of coronary artery [J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2023, 10(02): 33-36.
[14]	Yuan Liu, Yanhua Hao, Xiaoqian Cui, Hanwen Guan, Ziyu Wang, Yanni Liu. Public awareness of potential risks related to influenza in the context of COVID-19 prevention and control [J]. Chinese Journal of Hygiene Rescue(Electronic Edition), 2023, 09(01): 29-34.
[15]	Fengyi Qiu, Xingui Cai, Wenhuan He, Guijuan Zhang, Wah Yang. Research progress in knowledge, attitude and practice (KAP) of obesity, metabolic diseases and bariatric surgery [J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2023, 09(01): 38-42.

Please choose a citation manager

Content to export